What is this study trying to find out about brain-heart comorbidities?

This study aims to create a large database that collects detailed clinical, imaging, and sample data from patients with new cardiovascular-related diagnoses to better understand how heart and brain conditions are connected. The research uses artificial intelligence to analyze this data across multiple centers to improve knowledge and care. Beijing Tiantan Hospital leads this effort to build a comprehensive brain-heart comorbidity platform.

Who may be eligible for this brain-heart comorbidity clinical trial?

Adults aged 18 years and older who have been newly diagnosed with specific cardiovascular-related diseases such as ischemic heart disease, cardiac arrest, or atrial fibrillation may be eligible. There is no gender restriction. Participants must also agree to join the registry. Please review eligibility criteria for more details.

Is there any cost to participate in this brain-heart comorbidity clinical trial?

Study-related care, including all data collection and assessments, is provided at no cost. However, any personal travel or other expenses are not guaranteed to be covered and may vary. Participants can plan accordingly for any additional costs.

Actively Recruiting

Age: 18Years +

All Genders

ID05961748

Registry of Multicenter Brain-Heart Comorbidity in China

Led by Beijing Tiantan Hospital · Updated on 2023-09-21

100000

Participants Needed

Research Sites

N/A

Total Duration

AI-Summary

What this Trial Is About

Researchers are developing a large, multi-center database platform called the brain-heart comorbidity platform to collect and analyze clinical, sample, and imaging data from patients newly diagnosed with various cardiovascular-related diseases. This observational study aims to integrate artificial intelligence into this platform to enhance research on brain-heart comorbid conditions, supported by the National Key Research and Development Program. The platform stores data on a physical server or virtual appliance at participating institutions, connected through a network that allows for data queries and aggregation across centers. The study collects information on patients diagnosed with diseases identified by specific ICD-10-CM codes, including ischemic heart diseases, cardiac arrest, atrial fibrillation, heart failure, aortic diseases, subarachnoid hemorrhage, intracerebral hemorrhage, cerebral infarction, vascular occlusions, cerebral aneurysm, moyamoya disease, and arteriovenous malformations. Participants undergo multi-disciplinary assessments and their data is carefully checked for quality through a standardized process that removes incomplete or inaccurate records. The main outcomes measured include rates of all-cause mortality and cardiovascular events at discharge and 30 days. This ongoing registry enables continuous data collection and evaluation to better understand outcomes for patients with brain-heart comorbidities.

CONDITIONS

Brief Title

Registry of Multicenter Brain-Heart Comorbidity in China

Who Can Participate

Age: 18Years +

All Genders

Eligibility Criteria

You may qualify if you...

Age over 18 years old
Newly diagnosed with any cardiovascular-related disease identified by specific ICD-10-CM codes including ischemic heart diseases, cardiac arrest, atrial fibrillation/flutter, heart failure, aortic disease, subarachnoid hemorrhage, intracerebral hemorrhage, cerebral infarction, occlusion and stenosis of cerebral arteries, cerebral aneurysm, moyamoya disease, or arteriovenous malformation of cerebral vessels

You will not qualify if you...

Refusal to participate in the registry

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Diagnostic Evaluation

Duration - At discharge or within 30 days

Participants undergo multi-disciplinary assessments to evaluate brain-heart comorbidities.

1 to 2 visits depending on assessments

Long-term Monitoring

Duration - Up to 30 days after discharge

Participants are monitored for mortality and cardiovascular outcomes after initial evaluation.

Follow-up visits as needed within 30 days

Trial Site Locations

Total: 14 locations

Beijing Tiantan Hospital, Capital Medical University

Beijing, Beijing Municipality, China, 100070

Actively Recruiting

Beijing Anzhen Hospital, Capital Medical University